# Safety Alert

## March 2025

Esketamine nasal spray – Risks of Bradycardia and Seizure

## EDA performs label update to include the following:

**Undesirable effects:** 

**Cardiac Disorders:** 

Uncommon: Bradycardia

**Nervous System Disorders:** 

Rare: Seizure

### **Background:**

#### **Theraputic Indication**

Esketamine is indicated for :

- Adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode.
- Co-administered with oral antidepressant therapy, is indicated in adults with a moderate to severe episode of Major Depressive Disorder, as acute short-term treatment, for the rapid reduction of depressive symptoms, which according to clinical judgement constitute a psychiatric emergency.

<u>References:</u> EMA <u>(Click here)</u>